ClinicalTrials.gg
RecruitingNCT04351347Updated Mar 10, 2021

The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment

A Phase 2/3 interventional study of Ivermectin in COVID, sponsored by Tanta University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Tanta University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Sex
All
01

Study summary

Efficacy of Ivermectin in larger doses in COVID-19 treatment

Read the detailed description

Clinical Study Evaluating the Efficacy of Ivermectin in higher doses in COVID-19 treatment

02

Conditions studied

  • COVID
03

In context

Lead sponsor

Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with covid 19

Exclusion criteria

Exclusion Criteria:

  • Allergy or side effects to treatment
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Ivermectin

    Ivermectin alone in larger doses

    Drug: Ivermectin

  • No intervention
    Standard treatment

    Standard of care treatment

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients with improvement or died

    The number of patients with improvement or death

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2020 (actual). Primary completion is estimated for Dec 2030, 125 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2020
First posted
Apr 17, 2020
StartActual
Jun 16, 2020
Primary completionEst.
Dec 1, 2030
CompletionEst.
Dec 1, 2030
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04351347
Lead sponsor
Tanta University
Responsible party
Sherief Abd-Elsalam (Ass. Prof. Tropical Medicine, Tanta University) — Principal investigator
First posted
Apr 17, 2020
Start date
Jun 16, 2020
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Mar 10, 2021

Study contacts

Sherief Abd-Elsalam, ass. prof.
Contact
sheriefabdelsalam@yahoo.com
00201147773440
sherief Abd-Elsalam, Ass. Prof.
principal investigator · Tanta University - Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion